Uncategorised - European Medical Journal

Predictors of Psoriatic Arthritis in Juvenile Arthritis

Insights into predicting psoriatic arthritis (PsA) in juvenile idiopathic arthritis (JIA) patients, 18 years after their initial diagnosis, were shared in a recent study.

Burn Patients Face Pneumonia Risk Surge

A newly published study highlights a critical connection between inhalation injury severity and the risk of developing nosocomial pneumonia (NP) in burn patients.

Can Exercise and Brain Stimulation Help Patients With ALS?

A recent meta-analysis sheds light on nonpharmacologic treatments for amyotrophic lateral sclerosis (ALS), specifically active exercise and noninvasive brain stimulation (NIBS).

A Breakthrough for NAFLD and Type 2 Diabetes Management

Recent studies have highlighted the potential of sodium-glucose cotransporter 2 inhibitors, especially ertugliflozin, in improving outcomes for patients with NAFLD and T2DM.

3D Echocardiography with Vena Contracta Area Predicts Survival After Mitral TEER

3D-Vena Contracta Area (VCA) predicts one-year survival after mitral TEER, guiding better clinical decisions and outcomes.

Achieving Low Disease Activity in Lupus Reduces Organ Damage and Flare Risk

New research highlights that achieving low disease activity or remission in lupus patients significantly reduces organ damage and flare risks.

Handshake on a green background

Lilly gains EU backing for drug to treat Crohn’s disease

The drug has received a nod from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

Metabolic Imaging Distinguishes Ovarian Cancer Subtypes

Hyperpolarised 13C magnetic resonance spectroscopy can clinically distinguish between ovarian tumour subtypes.

New Study Uncovers the Role of MYO1F Protein in T Cell Metabolism and Cancer

Researchers have identified the protein MYO1F as a key regulator of T cell metabolism, with implications for immune responses, cancer, and autoimmune diseases…

Twice-Yearly Lenacapavir Shows Promise for HIV Prevention in Diverse Populations

A Phase 3 trial highlights the potential of twice-yearly subcutaneous lenacapavir as an effective PrEP option for diverse populations at risk of HIV infection.